Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?
MMF in IgA: Inching into the MAINstream?
Mycophenolate in IgAN - The Visual Abstract
Visual abstract for utility of MMF in IgAN by NSMC intern Dr Jeyakumar Meyyappan
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?
Welcome to #TenTweetNephJC!
— Nephrology Journal Club (@NephJC) April 28, 2023
✳️10 tweets #NephJC catch-up ✳️
On 3/28-29, #NephJC reviewed the MAIN trial (Mycophenolate monotherapy in IgA Nephropathy). Here are some pearls from the chat ⬇️ pic.twitter.com/RUepFSEwXx
Visual abstract for utility of MMF in IgAN by NSMC intern Dr Jeyakumar Meyyappan